CONTEXT: Octreotide causes significant tumour shrinkage in patients with acromegaly but the exact mechanism of action is unclear in vivo. OBJECTIVE: To determine the mechanism of action of octreotide in vivo using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). DESIGN: Five patients with acromegaly were treated with octreotide as primary medical therapy. DCE-MRI was done at baseline and 24 weeks. Local ethical committee approval was granted. SETTING: Study was done in a tertiary care centre. PATIENTS: Five patients with newly diagnosed acromegaly were recruited. INTERVENTION: Patients were started on subcutaneous octreotide and DCE-MRI was done on 0 and 24 weeks. MAIN OUTCOME MEASURES: Amplitude of contrast intake, exchange rate and maximum enhancement index of tumour tissue was compared before and after treatment. RESULTS: Amplitude of contrast intake (9.87 +/- 3.52 vs. 4.97 +/- 1.96 P < or = 0.05) and exchange rate (6.27 +/- 1.57 vs. 1.63 +/- 0.76 P value < or = 0.01) were significantly higher at baseline in adenoma compared to normal pituitary tissue but was comparable to normal pituitary tissue after treatment. There was a significant decrease in amplitude of contrast intake and exchange rate which relates to functional vascularity of adenoma at 24 weeks compared to baseline (P-values 0.026 and 0.002 respectively) but there were no significant changes in the normal pituitary tissue. CONCLUSION: DCE-MRI in acromegalic tumours treated with octreotide showed a significant reduction in functional vascularity after octreotide therapy compared to baseline in pituitary adenomas. This supports the antiangiogenic action of somatostatin analogue therapy in vitro, but it remains unclear if this mechanism is important clinically in analogue pre-treatment reducing the effect of radiotherapy on these pituitary tumours.
CONTEXT: Octreotide causes significant tumour shrinkage in patients with acromegaly but the exact mechanism of action is unclear in vivo. OBJECTIVE: To determine the mechanism of action of octreotide in vivo using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). DESIGN: Five patients with acromegaly were treated with octreotide as primary medical therapy. DCE-MRI was done at baseline and 24 weeks. Local ethical committee approval was granted. SETTING: Study was done in a tertiary care centre. PATIENTS: Five patients with newly diagnosed acromegaly were recruited. INTERVENTION: Patients were started on subcutaneous octreotide and DCE-MRI was done on 0 and 24 weeks. MAIN OUTCOME MEASURES: Amplitude of contrast intake, exchange rate and maximum enhancement index of tumour tissue was compared before and after treatment. RESULTS: Amplitude of contrast intake (9.87 +/- 3.52 vs. 4.97 +/- 1.96 P < or = 0.05) and exchange rate (6.27 +/- 1.57 vs. 1.63 +/- 0.76 P value < or = 0.01) were significantly higher at baseline in adenoma compared to normal pituitary tissue but was comparable to normal pituitary tissue after treatment. There was a significant decrease in amplitude of contrast intake and exchange rate which relates to functional vascularity of adenoma at 24 weeks compared to baseline (P-values 0.026 and 0.002 respectively) but there were no significant changes in the normal pituitary tissue. CONCLUSION:DCE-MRI in acromegalic tumours treated with octreotide showed a significant reduction in functional vascularity after octreotide therapy compared to baseline in pituitary adenomas. This supports the antiangiogenic action of somatostatin analogue therapy in vitro, but it remains unclear if this mechanism is important clinically in analogue pre-treatment reducing the effect of radiotherapy on these pituitary tumours.
Authors: Stefan Zwick; Gunnar Brix; Paul S Tofts; Ralph Strecker; Annette Kopp-Schneider; Hendrik Laue; Wolfhard Semmler; Fabian Kiessling Journal: Eur Radiol Date: 2009-09-01 Impact factor: 5.315
Authors: R Gostelow; C Scudder; S Keyte; Y Forcada; R C Fowkes; H A Schmid; D B Church; S J M Niessen Journal: J Vet Intern Med Date: 2017-02-01 Impact factor: 3.333